Krystal Biotech KRYS Q2 2026: Misses Estimates but VYJUVEK Keeps Growing
As seen on the 24/7 Wall St. homepage on August 3, 2026.
Krystal Biotech missed Q2 on both lines, but VYJUVEK's 24% revenue growth and a slate of pipeline readouts coming in the next 12 to 18 months signal the gene therapy company is ready to transition from single-product star to multi-product powerhouse.
Continue ReadingShow less
Krystal Biotech reported Q2 2026 revenue of $119.2 million, coming in about 1.5% below the consensus estimate of $121 million. Earnings per share of $1.79 also fell short, trailing the $1.91 estimate by roughly 6.5%. Despite the dual miss, the quarterly result still represents meaningful sequential and year-over-year progress — revenue has climbed from $70.3 million in Q2 2024 to $119.2 million in the most recent quarter, a steady upward trajectory across nine consecutive periods.
The growth engine behind those numbers is VYJUVEK, the company's approved gene therapy, which posted 24% revenue growth during the quarter. That kind of commercial momentum matters for a biotech that has so far depended almost entirely on a single product, and it gives Krystal a stronger financial foundation as it looks to broaden its portfolio.
Sponsored
Are You Ready To Retire, Or Years Behind?
Most Americans suspect they're behind on retirement and never find out. Advisor.com's free matching tool pairs you in about three minutes with a vetted fiduciary advisor who can help you with investing, taxes, retirement, estate planning, and more. No minimums. No sales call. Find out where you stand.
What investors will be watching most closely is the pipeline. Krystal has flagged a slate of readouts expected over the next 12 to 18 months, which the company frames as its path from a single-product story to a multi-product gene therapy platform. How those data points land will go a long way toward determining whether the current revenue trend can continue to accelerate.
Mentioned: KRYS